Received Apr 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 4 | B0005 | IM / LA |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | N/A | 391417 | IM / RA |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | 1 | LG5574 | IM / RA |
No adverse event reported. Reporting per Moderna after a temperature excursion, vaccine remained viable after the excursion per Moderna.
None reported
congential genu valgum, subluxation of right patella, osteoarthritis of knee, right foot drop, chronic thoracic back pain, pain in left ankle and joints of left foot, migraine headache, fibromyalgia, chronic flank pain, dizziness, chronic neck pain, drug induced movement disorder, anaplastic astrocytoma of brain, hypothyroidism, allergic rhinitis, GERD, asthma, hep C w/o coma, methamphetamine use disorder, alcohol use disorder, opioid use disorder, borderline personality disorder, bipolar 1 disorder, generalized anxiety disorder, attention deficit disorder, nicotine dependence, PTSD, elevated homocysteine, elevated BP without diagnosis of hypertension, drug-induced erectile dysfunction, gait instability
divalproex, buprenorphine-naloxone, estradiol valerate, progesterone micronized, spironolactone, nicotine, nicotine polacrilex, vorasidenib, esomeprazole magnesium, levothyroxine, sumatriptan, naloxone
penicillins, sulfonamide antibiotics, sulfadiazine, doxycycline, albuterol
N/A